Literature DB >> 32158110

Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema.

Sumeet P Mirgh1,2, Rayaz Ahmed1, Narendra Agrawal1, Sneha Bothra1, Bhaarat Mohan1, Ambar Garg1, Shinto Francis Thekkudan1, Vishvdeep Khushoo1, Dinesh Bhurani1.   

Abstract

Entities:  

Year:  2019        PMID： 32158110      PMCID： PMC7042422          DOI： 10.1007/s12288-019-01181-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  6 in total

1.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

2.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors:  Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal:  Lancet Oncol       Date:  2014-12-31       Impact factor: 41.316

3.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

Review 4.  Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.

Authors:  Hira Shaikh; Ahmed Khattab; Muhammad S Faisal; Abhishek Chilkulwar; Mary Albrethsen; Santhosh Sadashiv; Salman Fazal
Journal:  J Oncol Pharm Pract       Date:  2018-07-25       Impact factor: 1.809

Review 5.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

6.  Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Manuel Saenz-de-Viteri; Tomas Cudrnak
Journal:  Leuk Lymphoma       Date:  2018-09-06
  6 in total
  1 in total

1.  Cystoid macular edema secondary to ibrutinib.

Authors:  Ravid Ben-Avi; Dalia Dori; Itay Chowers
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.